Cytokinetics (CYTK) reported statistically positive Phase 3 ACACIA results for aficamten in non-obstructive hypertrophic cardiomyopathy, an outcome that bodes well for Edgewise Therapeutics (EWTX), as EDG-7500 is perhaps better suited mechanistically to address diastolic dysfunction in nHCM, Raymond James tells investors in a research note. The firm, which has a Strong Buy rating on Edgewise, views EDG-7500 as the most intriguing strategic asset in development in the HCM space.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics rises 23.3%
- Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
- JPMorgan ups Edgewise target, adds to Analyst Focus List
- Edgewise Therapeutics Completes Key Renal Study for EDG-7500, Setting Up Next Steps for Investors
- Edgewise Therapeutics’ sevasemten shows efficacy in Becker disorder